NCT05010330

Identify Prognostic Biomarkers of Lung Cancer

Multi-omics Combined With Clinical Data Analysis to Identify Prognostic Biomarkers of Lung Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.

Detailed description

Lung cancer is the leading cause of cancer-related death in China. In order to improve prognosis of lung cancer as well as provide new therapeutic targets, the identification of effective biomarkers for the prognosis of lung cancer is of great significance. It has been reported that some small molecules such as lncRNA, circRNA and polypeptides in human plasm have good prospects in diagnosing or evaluating the stage of diseases. In this study, we planned to use multi-omics combined with clinical data to discovery some small molecules that are potential to predict the prognosis of lung cancer patients. In addition, we want to construct a new risk score model that provide a candidate model for prognostic evaluation of lung cancer. And we hope our study can provide insights for precision immunotherapy of lung cancer by exploring the differences in clinical characteristics, tumor mutation burden, and tumor immune cell infiltration between different risk score groups.

Conditions

• Lung Cancer
• Lung Adenocarcinoma
• Lung Squamous Cell Carcinoma
• Non Small Cell Lung Cancer

Timeline

• Start date: 2020-07-01
• Primary completion: 2021-09-20
• Completion: 2021-09-30
• First posted: 2021-08-18
• Last updated: 2021-08-18

Locations

1 site across 1 country: China